A first-in-human phase 1 clinical study in healthy volunteers to assess the safety, tolerability and pharmacokinetics of EDI048, a novel promising agent to treat enteric cryptosporidiosis
{{output}}
Background: Cryptosporidiosis is a major diarrheal disease with significant morbidity and mortality in young and malnourished children from low- and middle-income countries. EDI048 is a novel Cryptosporidium PI(4)K inhibitor, des... ...
